Sherman M E, Schiffman M H, Strickler H, Hildesheim A
Department of Pathology, George Washington University Medical Center, Washington, D.C., USA.
Diagn Cytopathol. 1998 Jan;18(1):5-9. doi: 10.1002/(sici)1097-0339(199801)18:1<5::aid-dc2>3.0.co;2-g.
Cytologic screening in combination with ablative therapy has helped reduce cervical cancer mortality in the developed world. Despite the success of this approach, cervical cancer remains a major cause of death, especially among women with limited access to health care. Recognition that human papillomaviruses (HPVs) are the main etiologic agent in cervical cancer suggests that a prophylactic vaccine could reduce the incidence of HPV infection and, therefore, achieve cancer control with reduced reliance on costly screening programs. In this review, the rationale for developing a prophylactic HPV vaccine and the potential impact that vaccination would have on cervical cancer screening are discussed.
在发达国家，细胞学筛查与消融治疗相结合有助于降低宫颈癌死亡率。尽管这种方法取得了成功，但宫颈癌仍然是主要的死亡原因，尤其是在获得医疗保健机会有限的女性中。认识到人类乳头瘤病毒（HPV）是宫颈癌的主要病因表明，预防性疫苗可以降低HPV感染率，从而减少对昂贵筛查项目的依赖来实现癌症控制。在这篇综述中，讨论了开发预防性HPV疫苗的基本原理以及疫苗接种对宫颈癌筛查可能产生的影响。
